Sutro Biopharma Performance degli utili passati
Criteri Il passato verificati 0/6
Gli utili di Sutro Biopharma sono diminuiti a un tasso medio annuo di -21.8%, mentre il settore Biotechs ha visto gli utili crescere a un tasso medio annuo di 36.2%. I ricavi sono cresciuti crescere a un tasso medio annuo di 17.3%.
Informazioni chiave
-21.79%
Tasso di crescita degli utili
-5.83%
Tasso di crescita dell'EPS
| Biotechs Crescita del settore | 17.04% |
| Tasso di crescita dei ricavi | 17.31% |
| Rendimento del capitale proprio | n/a |
| Margine netto | -186.45% |
| Ultimo aggiornamento sugli utili | 31 Dec 2025 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Articolo di analisi • May 28
Industry Analysts Just Upgraded Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue Forecasts By 46%
Sutro Biopharma, Inc. ( NASDAQ:STRO ) shareholders will have a reason to smile today, with the analysts making...Seeking Alpha • May 01
Sutro Biopharma: Recycling Past Data Ahead Of The Readout, Sell
Summary Sutro Biopharma underwent major restructuring, including management changes, layoffs, and a 1-for-10 reverse split to maintain NASDAQ compliance. STRO's lead program, STRO-004, is a next-gen tissue factor-targeting exatecan ADC with a DAR of 8, aiming for Phase 1 data in mid-2026. Despite claims of improved safety via Fc-silencing and novel linker chemistry, prior ADCs (luveltamab tazevibulin) with similar strategies suffered high toxicities and discontinuation. Cash reserves and Vaxcyte equity holdings have dropped from ~$400M between 2023 to 2025 to $141.5M as of March 2026, raising sustainability concerns ahead of key clinical readouts. Read the full article on Seeking Alpha
Aggiornamento della narrazione • Apr 25
STRO: ADC Progress And Equity Offering Will Shape Balanced Future Outlook
Analysts have raised their price target for Sutro Biopharma by about $2, reflecting updated fair value estimates along with revised assumptions for the discount rate, revenue growth, profit margin and future P/E. What's in the News Sutro reported promising preclinical data for multiple next generation antibody drug conjugates (ADCs), including STRO-004, STRO-006 and STRO-227, at the American Association for Cancer Research Annual Meeting 2026.Aggiornamento della narrazione • Apr 10
STRO: Equity Offering And Lockup Structure Will Support Future Upside
Analysts now place Sutro Biopharma's price target at about $30.11, up from roughly $27.88. This reflects updated assumptions around fair value, discount rate, future revenue trends, profit margin, and a higher future P/E of about 199x.Aggiornamento della narrazione • Mar 27
STRO: Recent Equity Raises And Lockup Structure Will Support Future Upside
Analysts have revised their price target for Sutro Biopharma from $21.25 to $27.88, reflecting updated assumptions around discount rate, revenue growth, profit margin, and a higher future P/E in their models. What's in the News Sutro Biopharma filed a follow-on equity offering of up to US$100 million in common stock as an at-the-market program, providing flexibility to issue shares over time.
Aggiornamento della narrazione • Mar 10
STRO: Equity Raise And Index Removal Will Set Up Future Upside Potential
Analysts have kept their $51.00 price target on Sutro Biopharma unchanged, as a slightly lower discount rate and a higher assumed future P/E multiple are seen as offsetting a softer revenue outlook and reduced profit margin expectations. What's in the News Sutro Biopharma completed a follow on equity offering of approximately US$110.0 million, issuing 7,868,383 common shares at US$13.98 per share with a US$0.8388 discount per share (Key Developments).Aggiornamento della narrazione • Feb 24
STRO: Reverse Split And Equity Raise Will Support Future Upside
Analysts have inched up their price target on Sutro Biopharma to $21.25 from $21, citing updated assumptions that include a slightly lower discount rate, modest changes to long term profit margin expectations, and a higher future P/E multiple. What's in the News Sutro Biopharma completed a follow on equity offering of common stock, raising about US$110.0m through the sale of 7,868,383 shares at US$13.98 per share, reflecting a US$0.8388 per share discount (Key Developments).Aggiornamento della narrazione • Feb 09
STRO: Reverse Split And ADC Pipeline Progress Will Support Future Upside Potential
Analysts have maintained their price target on Sutro Biopharma at US$51.00, making only minor adjustments to their models. Slightly softer assumptions for long-term revenue growth and profit margins are largely offset by a higher future P/E multiple.Articolo di analisi • Feb 04
Here's Why We're A Bit Worried About Sutro Biopharma's (NASDAQ:STRO) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Aggiornamento della narrazione • Jan 26
STRO: Reverse Split And ADC Pipeline Progress Will Drive Future Upside
Analysts lifted their price target on Sutro Biopharma to US$51.00 per share, highlighting updated assumptions around fair value, discount rate, revenue growth expectations, profit margins, and a slightly lower future P/E as the key drivers of the change. What's in the News Sutro Biopharma regained compliance with Nasdaq’s continued listing standard for minimum share price under Rule 5450(a)(1) after its common stock maintained an average closing price of at least US$1.00 following a 1:10 reverse stock split effective December 3, 2025 (company announcement).Aggiornamento della narrazione • Jan 10
STRO: Reverse Split And ADC Pipeline Progress Will Support Future Upside
Analysts have trimmed their price target on Sutro Biopharma from US$22.29 to US$21.00, citing updated assumptions that include a slightly lower discount rate, a wider expected revenue decline of about 6.3 percentage points, a modestly higher profit margin, and a higher future P/E multiple. What's in the News Sutro Biopharma was removed from the Nasdaq Biotechnology Index, which can affect index fund ownership that tracks this benchmark (Index Constituent Drops).Articolo di analisi • Dec 31
Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 46%
Sutro Biopharma, Inc. ( NASDAQ:STRO ) shareholders would be excited to see that the share price has had a great month...Aggiornamento della narrazione • Dec 17
STRO: Reverse Split And ADC Pipeline Focus Will Drive Future Upside
Narrative Update on Sutro Biopharma Analysts have reduced their price target on Sutro Biopharma from approximately $28.00 to about $22.30 per share. This reflects a lower assumed future price to earnings multiple, while expectations for revenue growth and profit margins remain largely unchanged.Aggiornamento della narrazione • Dec 03
STRO: Reverse Split And ADC Focus Will Drive Long-Term Upside
Analysts have raised their price target on Sutro Biopharma from 2.69 dollars to 28.00 dollars, citing expectations for improved long term profit margins despite softer revenue growth assumptions and a modestly higher discount rate. What's in the News Sutro Biopharma approved a 1 for 10 reverse stock split or significant stock dividend effective December 3, 2025, aimed at improving its share price profile for investors (company announcement).Aggiornamento della narrazione • Sep 10
ADC Pipeline Focus Will Advance Preclinical Drug Development
The downward revision in Sutro Biopharma’s price target reflects worsening net profit margin and deeper negative revenue growth forecasts, with fair value decreasing from $3.11 to $2.69. What's in the News Sutro Biopharma entered a collaboration with the FDA to co-develop reference materials and improve regulatory standards for ADC drug development, leveraging Sutro's XpressCF technology and FDA's analytical capabilities.Articolo di analisi • Jul 01
Here's Why We're A Bit Worried About Sutro Biopharma's (NASDAQ:STRO) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Articolo di analisi • Apr 18
Benign Growth For Sutro Biopharma, Inc. (NASDAQ:STRO) Underpins Stock's 36% Plummet
Unfortunately for some shareholders, the Sutro Biopharma, Inc. ( NASDAQ:STRO ) share price has dived 36% in the last...
Nuova narrazione • Apr 03
ADC Pipeline Focus Will Advance Preclinical Drug Development
Strategic focus on preclinical programs and restructuring is set to drive future growth by enhancing drug development and revenue potential.Articolo di analisi • Mar 04
Sutro Biopharma, Inc. (NASDAQ:STRO) Not Doing Enough For Some Investors As Its Shares Slump 25%
To the annoyance of some shareholders, Sutro Biopharma, Inc. ( NASDAQ:STRO ) shares are down a considerable 25% in the...Seeking Alpha • Jan 02
Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless
Summary STRO's valuation remains compelling despite recent market hits, with optimism for a turnaround driven by late-stage clinical trials and strong pipeline potential. Luveltamab tazevibulin shows promising efficacy in ovarian cancer, with manageable toxicity, positioning it for potential Accelerated Approval by mid-2027. Financially, STRO has a two-year runway with current cash reserves, but further financing may be needed, risking shareholder dilution. Casting a wider net in pivotal trials carries risks but could expand patient eligibility, enhancing the overall investment thesis. Read the full article on Seeking AlphaArticolo di analisi • Nov 30
Why Investors Shouldn't Be Surprised By Sutro Biopharma, Inc.'s (NASDAQ:STRO) 26% Share Price Plunge
Unfortunately for some shareholders, the Sutro Biopharma, Inc. ( NASDAQ:STRO ) share price has dived 26% in the last...Articolo di analisi • Oct 11
Revenues Working Against Sutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Following 25% Dive
The Sutro Biopharma, Inc. ( NASDAQ:STRO ) share price has fared very poorly over the last month, falling by a...Seeking Alpha • Sep 23
Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology
Summary STRO specializes in ADCs for oncology, leveraging XpressCF and XpressCF+ platforms for precise antibody-drug conjugates without living cells. STRO-002, a promising ADC for ovarian cancer, has shown favorable safety and efficacy in trials, with potential FDA approval by 2026-2027. Collaborations with Merck, Vaxcyte, and Astellas Pharma could generate up to $3 billion in milestone payments. In my view, STRO's valuation appears cheap relative to its potential. It has ample resources to fund operations and research, making it a "strong buy" despite inherent biotech risks. Read the full article on Seeking AlphaArticolo di analisi • Aug 24
There's No Escaping Sutro Biopharma, Inc.'s (NASDAQ:STRO) Muted Revenues Despite A 29% Share Price Rise
Sutro Biopharma, Inc. ( NASDAQ:STRO ) shares have had a really impressive month, gaining 29% after a shaky period...Articolo di analisi • Aug 22
Brokers Are Upgrading Their Views On Sutro Biopharma, Inc. (NASDAQ:STRO) With These New Forecasts
Celebrations may be in order for Sutro Biopharma, Inc. ( NASDAQ:STRO ) shareholders, with the analysts delivering a...Articolo di analisi • Aug 16
Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results
Sutro Biopharma, Inc. ( NASDAQ:STRO ) defied analyst predictions to release its quarterly results, which were ahead of...Articolo di analisi • Jun 26
The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet As Shares Tumble 28%
Unfortunately for some shareholders, the Sutro Biopharma, Inc. ( NASDAQ:STRO ) share price has dived 28% in the last...Articolo di analisi • May 31
We Think The Compensation For Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Looks About Right
Key Insights Sutro Biopharma to hold its Annual General Meeting on 6th of June Salary of US$686.7k is part of CEO Bill...Articolo di analisi • Apr 02
Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates
Market forces rained on the parade of Sutro Biopharma, Inc. ( NASDAQ:STRO ) shareholders today, when the analysts...Articolo di analisi • Mar 28
The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet
With a price-to-sales (or "P/S") ratio of 2x Sutro Biopharma, Inc. ( NASDAQ:STRO ) may be sending very bullish signals...Articolo di analisi • Dec 19
Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%
Sutro Biopharma, Inc. ( NASDAQ:STRO ) shares have had a really impressive month, gaining 43% after a shaky period...Articolo di analisi • Aug 24
Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Feb 10
Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Jan 12
An Intrinsic Calculation For Sutro Biopharma, Inc. (NASDAQ:STRO) Suggests It's 47% Undervalued
Key Insights Sutro Biopharma's estimated fair value is US$13.8 based on 2 Stage Free Cash Flow to Equity Current share...Ripartizione dei ricavi e delle spese
Ripartizione dei ricavi e delle spese
Come Sutro Biopharma guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Dec 25 | 102 | -191 | 41 | 0 |
| 30 Sep 25 | 106 | -217 | 41 | 0 |
| 30 Jun 25 | 104 | -209 | 47 | 0 |
| 31 Mar 25 | 66 | -245 | 49 | 0 |
| 31 Dec 24 | 62 | -227 | 48 | 0 |
| 30 Sep 24 | 161 | -124 | 56 | 0 |
| 30 Jun 24 | 169 | -124 | 57 | 0 |
| 31 Mar 24 | 154 | -115 | 60 | 0 |
| 31 Dec 23 | 154 | -107 | 63 | 0 |
| 30 Sep 23 | 49 | -172 | 60 | 0 |
| 30 Jun 23 | 57 | -143 | 60 | 0 |
| 31 Mar 23 | 75 | -130 | 60 | 0 |
| 31 Dec 22 | 68 | -119 | 60 | 0 |
| 30 Sep 22 | 70 | -123 | 61 | 0 |
| 30 Jun 22 | 53 | -134 | 63 | 0 |
| 31 Mar 22 | 53 | -114 | 60 | 0 |
| 31 Dec 21 | 62 | -106 | 56 | 0 |
| 30 Sep 21 | 60 | -127 | 48 | 0 |
| 30 Jun 21 | 69 | -79 | 41 | 0 |
| 31 Mar 21 | 50 | -43 | 39 | 0 |
| 31 Dec 20 | 43 | -32 | 37 | 0 |
| 30 Sep 20 | 46 | 13 | 38 | 0 |
| 30 Jun 20 | 40 | -17 | 36 | 0 |
| 31 Mar 20 | 41 | -61 | 34 | 0 |
| 31 Dec 19 | 43 | -56 | 33 | 0 |
| 30 Sep 19 | 51 | -42 | 32 | 0 |
| 30 Jun 19 | 46 | -40 | 29 | 0 |
| 31 Mar 19 | 41 | -38 | 25 | 0 |
| 31 Dec 18 | 38 | -35 | 22 | 0 |
| 30 Sep 18 | 23 | -49 | 18 | 0 |
| 30 Jun 18 | 33 | -40 | 18 | 0 |
| 31 Mar 18 | 42 | -30 | 17 | 0 |
| 31 Dec 17 | 52 | -20 | 16 | 0 |
| 31 Dec 16 | 60 | 0 | 15 | 0 |
Guadagni di qualità: STRO al momento non è redditizia.
Margine di profitto in crescita: STRO al momento non è redditizia.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: STRO non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 21.8% all'anno.
Accelerare la crescita: Impossibile confrontare la crescita degli utili di STRO nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia
Guadagni vs Settore: STRO non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( 54.5% ).
Rendimento del capitale proprio
ROE elevato: Le passività di STRO superano le sue attività, quindi è difficile calcolare il suo rendimento del capitale proprio.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/30 10:18 |
| Prezzo dell'azione a fine giornata | 2026/05/29 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Sutro Biopharma, Inc. è coperta da 20 analisti. 12 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Lukas Shumway | Barclays |
| Zhiqiang Shu | Berenberg |
| Tazeen Ahmad | BofA Global Research |